Tailor-made renal cell carcinoma vaccines.
Cancer vaccines are beginning to show signs of clinical activity, but major uncertainties remain regarding antigen selection, strategy for immune stimulation, patient stratification, and monitoring of elicited response. A new study of peptide vaccines in advanced renal cell carcinoma patients provides important insights into these central issues.